Search results
Results from the WOW.Com Content Network
[45] [46] Moreover, the lifetime incidence of breast cancer in men is approximately 0.1%, [47] the average age of diagnosis of prostate cancer and male breast cancer are similar (around 70 years), [10] [48] and millions of men have been treated with bicalutamide for prostate cancer, [49] all of which are potentially in support of the notion of ...
Along with triptorelin and goserelin, it has been used to delay puberty in transgender youth until they are old enough to begin hormone replacement therapy. [17] Researchers have recommended puberty blockers after age 12, when the person has developed to Tanner stages 2–3, and then cross-sex hormones treatment at age 16.
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Estrogen is the predominant sex hormone that slows bone loss (even in men). Both estrogen and testosterone help stimulate bone formation (T, especially at puberty). Testosterone may cause an increase in cortical bone thickness in transgender men (however this does not necessarily translate to a greater mechanical stability).
The study was prematurely terminated when previously unexpected risks were discovered, specifically the finding that though the all-cause mortality was not affected by the hormone therapy, the benefits of menopausal hormone therapy (reduced risk of hip fracture, colorectal and endometrial cancer and all other causes of death) were offset by ...
Those that have advanced to human trials show stronger effects in bone and muscle tissue and weaker effects in the prostate. [ 8 ] Unlike most current forms of testosterone replacement, SARMs are orally bioavailable [ 7 ] and largely eliminated via hepatic metabolism and metabolized through amide hydrolysis in the case of arylpropionamides and ...
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
Gender-affirming hormone therapy (GAHT), also called hormone replacement therapy (HRT) or transgender hormone therapy, is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity.